**4. Conclusions**

Nonalcoholic fatty liver disease and its evolution, Non-alcoholic steatohepatitis, constitute a serious cardiometabolic inflammatory process of the liver. Lifestyle modifications such as continued gradual weight loss and exercise are the cornerstone of the therapeutic treatment and have a profound beneficial effect on liver function tests and the co-existing cardiovascular risk. Bariatric surgery could also be advised for certain patients. Several medications have been tried for the treatment

*Therapeutic Approach to NAFLD-NASH DOI: http://dx.doi.org/10.5772/intechopen.107487*

of NAFLD/NASH, especially medications that ameliorate the metabolic profile of the patients, insulin sensitivity and lipid oxidation, thus decreasing the lipid burden and improving steatosis and inflammation. Certain new agents have also been under development and show quite promising in the treatment of this complex condition. The implementation of a variety of new agents that target the mechanisms of inflammation and fibrosis in the pathogenesis of NAFLD/NASH will lead us to new effective treatments that will halt the acceleration of the disease and restore normal physiology of the hepatic tissue. Combination therapies may offer a further beneficial effect, but further studies need to be conducted to prove their efficiency.
